glutathione and long haul covid COVID”—A hypothesis for understanding the biological basis pharmacological treatment strategy - Jarrott - 2022 - Pharmacology Research & Perspectives Frontiers | Metabolomic and immune

However, in order to realize the full therapeutic potential of ferroptosis-based therapies, it is critical that we first acquire a fundamental understanding of the biochemical and molecular pathways regulating ferroptosis, and its biological roles within physiological contexts

MSCs also modulate the pathogenesis of DKD by acting as anti-inflammatory mediators in renal TECs (216)

PMID: 39767244

Nguyen 13 , Volker Puetz 1 1 Department of Neurology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany, 2 Institute of Neuroradiology, Dresden Neurovascular Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany, 3 Radiology and Radiation Oncology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, 4 Department of Neurology, University of Toledo, Toledo, United States, 5 Department of Neurology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, 6 Departments of Neurology and Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, United States, 7 Department of Neurology, Klinikum Ludwigshafen, Ludwigshafen, Germany, 8 Department of Neurology, UZ Leuven, Laboratory for Neurobiology, KU Leuven, Leuven, Belgium, 9 Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, 10 Department of Neurology, Hpital Civil Marie Curie, Charleroi, Belgium, 11 Department of Neurology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, 12 Department of Neurology, Hospital Vall d'Hebron, Barcelona, Spain, 13 Radiology, Radiation Oncology and Neurology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, United States Background and Aims: There is uncertainty about whether patients with M2 occlusion benefit from endovascular therapy (EVT) in the late (6-to-24 hour) time window